What question did this study set out to answer?

The aim is to understand the mechanisms of chemoresistance in pancreatic cancer and to evaluate the effectiveness of combined RAS inhibition and immune checkpoint blockade.

April 5, 2026Cancer Research

Combined RAS and Immune Checkpoint Inhibition Targets NF-KB in Chemoresistant Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

The aim is to understand the mechanisms of chemoresistance in pancreatic cancer and to evaluate the effectiveness of combined RAS inhibition and immune checkpoint blockade.
Generated chemoresistant pancreatic ductal adenocarcinoma models through orthotopic implantation in mice
Analyzed tumor microenvironment using flow cytometry, RNA sequencing, and immunohistochemistry
Investigated NF-κB signaling in relation to cytokine expression and immune checkpoint expression
Conducted in vivo experiments combining MRTX1133 with anti-CTLA-4 or anti-PD1 therapy
MRTX1133 treatment significantly reduced tumor volumes and weights compared to controls
KRAS pathway was significantly upregulated in chemoresistant tumors
Increased expression of cytokines CXCL10 and CCL2, while GM-CSF and LIF decreased in MRTX1133 treated tumors
Combination therapy improved immune infiltration and prolonged survival compared to monotherapy

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Investigates NF-KB-driven immune evasion and proposes combination therapy in chemoresistant pancreatic cancer, suggesting potential treatment improvements.

Cite This Study

Gulay et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd13a79560c99a0a2f04 https://doi.org/10.1158/1538-7445.am2026-1871

View Full Paper

Ask AI

Bookmark

Implication

Investigates NF-KB-driven immune evasion and proposes combination therapy in chemoresistant pancreatic cancer, suggesting potential treatment improvements.

Combined RAS and Immune Checkpoint Inhibition Targets NF-KB in Chemoresistant Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Combined RAS and Immune Checkpoint Inhibition Targets NF-KB in Chemoresistant Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading